About Lifecore Biomedical Webcast Scheduled for Thursday, August 7 at 4:30 p.m. Eastern CHASKA, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it will report financial results for the fourth quarter and fiscal year 2025 on Thursday, August 7, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore's senior management team will host a ...

Core Viewpoint - BGM Group Ltd is undergoing a significant leadership transition aimed at enhancing its technological transformation and sustainable growth, with a focus on innovation and strategic upgrades in response to market opportunities and challenges [1][5]. Leadership Changes - Mr. Zhanchang Xin has resigned as Chairman, effective March 1, 2025, and will be succeeded by Mr. Chen Xin, the current CEO [2][3]. - Mr. Chen Xin has extensive experience in market consolidation and corporate management, having led the acquisition of Duxiaobao Intelligent Technology and previously worked in autonomous driving algorithm development [3][4]. - Mr. Lin Zhang has been appointed as an independent director and will chair the compensation committee, bringing rich experience in AI model architecture and deep learning projects [4][5]. Strategic Focus - The company is strategically focused on technology fields including AI applications, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals [6]. - BGM Group utilizes big data mining and AI Agent technology to provide comprehensive AI solutions and intelligent robot services, particularly in the insurance sector [7]. - In biopharmaceuticals, the company produces key products like oxytetracycline API and crude heparin sodium, integrating AI-assisted decision-making to optimize production and supply chain processes [8].